Proactive investorsLogo Proactive Investors UK Website

Search field

1 year chart

digital-look imported chart image

1 day chart

digital-look imported chart image
Epic & Msn data
Epic EHP
Time: 16:53:48
Mid Price: 435.00
Change Today: 0.00
Change % Today: 0.00
Fifty Two Week High: 450.00
Fifty Two Week Low: 262.50
Market Capital: 34.51
Period & price data
Period Price
Now: 435.00
3 Months ago:
6 Months ago:
1 Year ago:
Additional information
Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
Epic: EHP
News: Latest news
Web Site: EpiStem Holdings Plc
Other Articles: 09-03-201004-02-201014-12-2009

EpiStem Holdings Plc

Epistem is a biotechnology company applying its expertise in epithelial stem cells in the areas of oncology and gastrointestinal diseases as well as dermatological applications. Epistem has become recognised as a specialist in epithelial tissue and stem cell analyses. Our heritage is based on our expert science and know-how in the field of epithelial tissue and adult epithelial stem cell biology.

CLICK HERE FOR FULL ANLAYSIS OF EPISTEM HOLDINGS PLC
Friday, July 31, 2009

Stem Cell specialist Epistem says trading strong, expects maiden full year profit

company news image

Adult epithelial stem cell specialist, Epistem plc (AIM: EHP) confirmed yesterday that it would post a maiden profit after tax for the full year ending 30 June 2009, thanks to “strong” trading and a tax credit from the prior year.


Shares in Epistem were little moved on the announcement, not entirely unsurprising when looking at the strong appreciation in its share price over the past few months.  Clearly the market was confident that the company would hit its numbers, and the market is not often wrong.


Epistem’s recent share price performance places is amongst the best performing stocks in the biotechnology and pharmaceutical sector, in spite of two of its largest shareholders, Helium Special Situations Fund and Calculus Capital, both taking advantage of recent gains to trim their holdings to 9.4% and 13.99% respectively.


The company’s business model is based around leveraging its intellectual property and the expertise in stem cell research. The company’s three divisions include: Novel Therapies, which looks to find preclinical leads for new drugs; Contract Research, which looks at the preclinical efficacy of third party new drug compounds; and Biomarkers, which work with both preclinical and clinical stage drugs in development.

Both Daniel Stewart and Piper Jaffray (Nomad and House Broker) have a ‘buy’ stance on Epistem. Daniel Steward if forecasting full year (June 30 2010) profit before tax of £0.8 million on revenues of £5.3 million.  Piper Jaffray is slightly more bullish, anticipating FY 2010 profit before tax of £0.9 million on revenues of £5.5 million.

NewsNow icon AddThis Feed Button
Register here to be notified of future EpiStem Holdings Plc articles.

Other EpiStem Holdings Plc articles

More articles ►

Other EpiStem Holdings Plc news

More news ►

Investors interested in EpiStem Holdings Plc recently viewed


No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.